April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Ocular Side Effects Of Inhibitors Of The Epidermal Growth Factor Receptor: Report Of 4 Cases
Author Affiliations & Notes
  • Nicolas Molina
    Hospital Clinic of Barcelona, Barcelona, Spain
  • Raoul A. Saint-Jean
    Hospital Clinic of Barcelona, Barcelona, Spain
  • Josep Torras
    Hospital Clinic of Barcelona, Barcelona, Spain
  • Merce Morral
    Hospital Clinic of Barcelona, Barcelona, Spain
  • Maite Sainz de la Maza
    Hospital Clinic of Barcelona, Barcelona, Spain
  • Footnotes
    Commercial Relationships  Nicolas Molina, None; Raoul A. Saint-Jean, None; Josep Torras, None; Merce Morral, None; Maite Sainz de la Maza, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 1997. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Nicolas Molina, Raoul A. Saint-Jean, Josep Torras, Merce Morral, Maite Sainz de la Maza; Ocular Side Effects Of Inhibitors Of The Epidermal Growth Factor Receptor: Report Of 4 Cases. Invest. Ophthalmol. Vis. Sci. 2011;52(14):1997.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose:
 

To describe the ocular effects associated with the administrationof epidermal growth factor (EGF) receptor inhibitors, Panitumumaband Erlotinib.

 
Methods:
 

Noncomparative interventional case series included 8 eyes of4 patients in treatment with EGF receptor inhibitors, 3 withErlotinib for end-stage lung carcinoma and 1 with Panitumumabfor end-stage colorectal cancer.

 
Results:
 

Multiple epithelial defects were observed in 8 eyes, cornealmelting and thinning were observed in 3 eyes of 2 patients,2 eyes of 1 patient presented with lower lid ectropion, andcorneal perforation in 2 eyes of 2 patients, both requiringa penetrating keratoplasty.

 
Conclusions:
 

Severe ocular side effects, including perforated corneal ulcers,may be associated with the use of the EGF inhibitors panitumaband erlotinib.  

 

 
Keywords: cornea: clinical science • growth factors/growth factor receptors • clinical (human) or epidemiologic studies: outcomes/complications 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×